Haemonetics Corp (HAE.N) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Haemonetics Corp reaffirms FY 2015 guidance; gives FY 2016 guidance


Wednesday, 30 Jul 2014 06:00am EDT 

Haemonetics Corp:Says overall FY 2015 revenue is affirmed at decline of 0 pct. -2 pct. with $40-$50 mln of revenue growth from identified growth drivers more than offset by $50-$55 mln of revenue headwind from net volume and pricing declines in the U.S. blood center business and weakness in Japanese Yen.Affirms FY 2015 expectations for adjusted operating income (EBIT) of $140-$150 mln and adjusted earnings per share (EPS) in range of $1.85 to $1.95.Expects to return to mid-single digit revenue growth rate and double digit adjusted operating income and earnings per share growth rates in FY 2016.Reported revenue of $938.51 mln in FY 2014.FY 2015 revenue of $927.83 mln, EBIT of $143 mln and EPS of $1.89 - Thomson Reuters I/B/E/S.FY 2016 revenue of $964.97 mln, EBIT of $152.96 mln and EPS of $2.21 - Thomson Reuters I/B/E/S.